The content on this site is intended for healthcare professionals only
Prof Mateos talks to ecancer at ASH 2016 to discuss the efficacy of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory myeloma (RRMM), based on prior lines of therapy.
The data represents an update to the CASTOR study (Palumbo A. N Engl J Med 2016).
The treatment benefit of DVd vs Vd was maintained across 1 to 3 prior and 1 prior line patients. Responses for DVd were deep and durable and correlated with significantly improved outcomes versus Vd.
Despite small group sizes, treatment benefit of DVd vs Vd was also observed in high-risk cytogenetic pts receiving 1-3 PL.
These data continue to support the addition of daratumumab to a standard-of-care regimen in RRMM.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Multiple Myeloma: evolving paradigm - Panel Discussion
Advancements in paediatric Acute lymphoblastic leukemia management
